ALOGLIPTIN

 ALOGLIPTIN

BRAND NAME:-VIPIDIA & many brands available in INDIA

ALOGLIPTIN is an oral anti-diabetic drug in the DPP-4 (dipeptidyl peptidase-4 ) inhibitor (gliptin) class.Alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in people whose diabetes cannot adequately be controlled with metformin alone.

MECHANISM OF ACTION:-

Alogliptin inhibits dipeptidyl peptidase 4 (DPP-4), which normally degrades the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 ( GLP-1). The inhibition of DPP-4 increases the amount of active plasma incretins which helps with glycemic control. GIP and GLP-1 stimulate glucose dependent secretion of insulin in pancreatic beta cells. GLP-1 has the additional effects of suppressing glucose dependent glucagon secretion, inducing satiety, reducing food intake, and reducing gastric emptying.

USED:- decrease the blood sugar levels 

SIDE EFFECTS:-

mild hypoglycemia based on clinical studies.Alogliptin is not associated with increased weight, increased risk of cardiovascular events. It may also cause joint pain that can be severe and disabling.

ALOGLIPTIN IS MARKETED IN JAPAN .